We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

101 hedge funds and large institutions have $749M invested in Epizyme, Inc in 2017 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 27 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more call options, than puts

Call options by funds: $2.27M | Put options by funds: $1.16M

48% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 27

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

3% less funds holding

Funds holding: 104101 (-3)

12% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 17

35% less capital invested

Capital invested by funds: $1.15B → $749M (-$402M)

Holders
101
Holders Change
-3
Holders Change %
-2.88%
% of All Funds
2.29%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
15
Increased
40
Reduced
27
Closed
17
Calls
$2.27M
Puts
$1.16M
Net Calls
+$1.11M
Net Calls Change
-$673K
Name Holding Trade Value Shares
Change
Change in
Stake
MLICM
76
Metropolitan Life Insurance Company (MetLife)
New York
$199K -$215K -14,809 -48%
TD Asset Management
77
TD Asset Management
Ontario, Canada
$183K +$212K +14,600 New
JMPWA
78
JP Morgan Private Wealth Advisors
California
$179K
CSS
79
Cubist Systematic Strategies
Connecticut
$174K +$201K +13,838 New
UBS Group
80
UBS Group
Switzerland
$152K -$346K -23,790 -66%
Legal & General Group
81
Legal & General Group
United Kingdom
$146K +$5.28K +363 +3%
BTS
82
BB&T Securities
Virginia
$138K
JP Morgan Chase
83
JP Morgan Chase
New York
$133K -$2.15M -147,831 -93%
UBS AM
84
UBS AM
Illinois
$128K
BNP Paribas Financial Markets
85
BNP Paribas Financial Markets
France
$126K +$72.6K +4,996 +98%
Parallax Volatility Advisers
86
Parallax Volatility Advisers
California
$94K +$109K +7,476 New
NIT
87
NumerixS Investment Technologies
British Columbia, Canada
$77K +$30.5K +2,100 +53%
Simplex Trading
88
Simplex Trading
Illinois
$64K +$74.7K +5,140 New
Canada Life
89
Canada Life
Manitoba, Canada
$60K
AIP
90
Ameritas Investment Partners
Nebraska
$52K +$13.6K +938 +29%
CG
91
Cutler Group
California
$44K +$49.6K +3,414 +2,943%
LWCFA
92
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$38K
Federated Hermes
93
Federated Hermes
Pennsylvania
$30K -$590K -40,621 -94%
Royal Bank of Canada
94
Royal Bank of Canada
Ontario, Canada
$22K -$52.8K -3,631 -68%
Pacer Advisors
95
Pacer Advisors
Pennsylvania
$14K +$16K +1,100 New
Zurich Cantonal Bank
96
Zurich Cantonal Bank
Switzerland
$12K
LTFS
97
Ladenburg Thalmann Financial Services
Florida
$6K -$1.63K -112 -20%
RFM
98
Royal Fund Management
Florida
$3K
PHK
99
Point72 Hong Kong
Hong Kong
$1K -$2.46K -169 -79%
MAM
100
Meeder Asset Management
Ohio
$1K +$451 +31 +74%

EPZM Hedge Fund Activity: Q4 2017 in Review

101 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q4 2017, worth a combined $749M — down 35% from $1.15B a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of EPZM and 15 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 40 added.

The largest buyer was Redmile Group, adding an estimated $10.4M. The largest seller was Fidelity Investments, cutting an estimated $38.3M.

  • 101 institutional investors held Epizyme, Inc (EPZM) as of Q4 2017, down from 104 in Q3 2017.
  • Funds reported $749M of Epizyme, Inc stock for Q4 2017, down 35% quarter-over-quarter.
  • 15 funds opened new Epizyme, Inc positions in Q4 2017 and 17 closed out, a net change of -2 holders.
  • The largest Epizyme, Inc buyer in Q4 2017 was Redmile Group, an estimated $10.4M added.
  • The largest Epizyme, Inc seller in Q4 2017 was Fidelity Investments, an estimated $38.3M sold.

Based on aggregated 13F filings for Q4 2017.